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Abstract: Neuropathic pain in cancer is common and debilitating. It is important to differentiate
neuropathic pain from other cancer-related pains as it is associated with worse pain outcomes and
requires different treatment strategies. This review summarises recent updates to pain classification,
aetiology, pain assessment and current recommendations for treatment in patients with cancer-related
neuropathic pain.
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1. Definitions and Epidemiology
Neuropathic pain is defined as “pain caused by a lesion or disease affecting the somatosensory
system” [1] and may lead to both loss of function and also increased pain sensitivity and spontaneous
pain [2,3]. It is common in cancer, resulting from direct damage to the nervous system from a primary
tumour or metastases, or from cancer treatment, such as chemotherapy [4]. Neuropathic pain is usually
chronic, either persisting continuously or characterised by recurrent painful episodes [2].
Neuropathic pain is different from nociceptive pain, which is defined as “pain that arises from
actual or threatened damage to non-neural tissue and is due to the activation of nociceptors” [5].
In nociceptive pain, the somatosensory nervous system is functionally normally, contrasting
with abnormal function underlying neuropathic pain. It is estimated that 20% of cancer pain is
purely neuropathic in origin [6]. However, when mixed neuropathic-nociceptive pain is included,
approximately 40% of patients with cancer are affected by neuropathic pain [6].
Neuropathic cancer pain is associated with poor outcomes [7,8]. A study in 2012 found
that neuropathic cancer pain was associated with more oncological treatment, greater analgesic
requirements (including strong opioids and adjuvant analgesics) and reduced performance status than
those with nociceptive pain [8]. Patients with neuropathic pain also reported worse physical, cognitive,
and social functioning [8].
In recognition of the importance of identifying neuropathic pain, the latest International
Association for the Study of Pain (IASP) classification of chronic pain for International Classification
of Diseases (ICD-11) identifies specific codes for chronic neuropathic cancer pain (neuropathic pain
caused by tumour), as well as neuropathic pain caused by treatments, such as chemotherapy or
radiotherapy [4]. The IASP guidance emphasises the importance of a correct diagnosis of the pain
in cancer so that tailored treatment (including analgesia, anticancer therapies, surgery and non-drug
interventions) can optimise pain outcomes [9].
2. Aetiology
The aetiology of cancer-related neuropathic pain is diverse. Cancer-related neuropathic pain
is conventionally subdivided into tumour-related and treatment-related pains. Not all pain in a
cancer patient is cancer-related; pain from comorbid diseases is common, particularly in older
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patients [10]. About two-thirds of neuropathic pain in cancer patients is tumour-related (neuropathic
cancer pain [NCP]), around 20% results from cancer treatment and 10–15% from comorbid diseases [6].
The proportion of pain caused by cancer treatment is higher in neuropathic pain compared with all
types of cancer pain [6].
NCP may result from direct infiltration by the primary tumour or metastases into components of
the peripheral or central nervous system. Examples of involvement of the peripheral nervous system
include invasion of the brachial plexus by thoracic tumours, or invasion of the lumbosacral plexus
by abdominal or pelvic tumours. A typical example of involvement of the central nervous system is
spinal cord compression resulting from vertebral collapse due to bony metastatic disease.
Paraneoplastic neurological syndromes can also occur, resulting from remote effects of cancer
mediated by the immune system [11]. They can affect the function of the nervous system at any level,
including the central nervous system, peripheral nervous system, neuromuscular junction and muscle
itself [11]. The most frequent paraneoplastic neurological syndromes are paraneoplastic cerebellar
degeneration and sensory neuronopathy [11,12].
Cancer therapy-induced neuropathic pain can result as an unintended consequence (side
effect) or complication from cancer treatments, including surgery, radiotherapy and chemotherapy.
Surgical intervention may cause direct damage to peripheral nerves. Examples of interventions
commonly associated with post-traumatic neuropathic pain syndromes include mastectomy and
thoracotomy [4,10].
Radiation treatment can result chronic painful radiation-induced neuropathy. Delayed local
damage to the nervous system in the field of radiotherapy is common [4], sometimes manifesting
months or even years following treatment [10]. It is often progressive and irreversible [4].
The underlying mechanisms are not fully understood. It may result from nerve compression from
radiation-induced fibrosis, but also from direct nerve and blood vessel injury from microvascular
changes [13]. Brachial plexopathy following irradiation for lung or breast cancer is a classic example
of radiation-induced neuropathy [14]. Other less common examples include painful lumbosacral
plexopathy after pelvic radiotherapy [13,15] and axial neuropathy of the spinal cord following cervical
radiotherapy [4].
Chemotherapy-induced peripheral neuropathy (CIPN) is a common, painful and dose-limiting
side effect of chemotherapy [10]. It is generally dose-dependent [16]. Typically, symptoms begin in the
first two months of treatment, worsen as treatment progresses and then stabilise soon after cessation.
However, symptoms can persist long after treatment. A systematic review in 2014 found that CIPN
affects 60% of patients 3 months after treatment, and 30% at 6 months or more [17]. Common neurotoxic
chemotherapeutics include the taxanes (paclitaxel and docetaxel), platinum-based drugs (cisplatin and
oxaplatin), vinca alkaloids (vincristine), thalidomide and proteasome inhibitors (bortezomib) [4,10,16].
CIPN most commonly results from direct neurotoxic effects of chemotherapy on dorsal root ganglion
neurons or their axons, causing pain in a stocking-and-glove distribution, sensory loss and sensory
ataxia [16]. The pain is often characterised by pricking or burning, or an “electric sensation” [4].
Autonomic, motor and occasionally cranial nerve involvement can less commonly occur [16].
3. Assessment
Clinically, neuropathic pain is a heterogeneous entity, comprising many and varied positive and
negative symptoms. Positive symptoms include pain, both spontaneous and evoked. Spontaneous
pain can be continuous or paroxysmal. Evoked pain can result from non-nociceptive stimuli (e.g.,
pressure from tight clothes or stroking) causing allodynia, or as an increased response to a nociceptive
stimulus causing hyperalgesia [2,18]. Characteristics of neuropathic pain include shooting, sharp,
stabbing, tingling, pricking, electric shocks and pins and needles [19,20]. Negative symptoms include
decreased or loss of sensation to light touch and vibration (hypoesthesia) and pain (hypoalgesia) [21].
Autonomic features sometimes associated with neuropathic pain include mottled skin, sweating,
redness or swelling [20].
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Neuropathic pain can be difficult to identify, particularly in the context of cancer pain, where other
processes, such as pre-existing neurological disease or muscle spasticity from disorders of the motor
system, may confuse the clinical picture [22]. This has implications both in clinical and research settings.
In clinical practice this may lead to under recognition, and therefore undertreatment, of neuropathic
pain. In research, inadequate pain assessment can lead to heterogeneous sample populations and an
increasing number of neuropathic pain studies failing to reach their primary efficacy end point [23,24],
resulting in a poor evidence base for treatment recommendations.
In an effort to address this, in 2016 the International Study for the Study of Pain (IASP) Special
Interest Group on Neuropathic Pain (NeuPSIG) proposed an updated grading system for assessment
of neuropathic pain, for use in both clinical and research settings (Figure 1). This system stratifies pain
into possible, probable and definite neuropathic pain [22]. The assessment criteria include: (1) history
of relevant neurological lesion or disease and neuroanatomically plausible distribution of pain; (2) pain
associated with sensory signs in the same plausible neuroanatomical distribution; and (3) a diagnostic
test confirming the presence of a lesion or disease of the somatosensory nervous system that explains
the pain. Satisfying these three criteria in turn raises the likelihood of neuropathic pain from possible
to probable to definite. The authors suggest that a “probable” diagnosis of neuropathic pain should be
sufficient to initiate treatment for neuropathic pain. They also suggest that “definite” diagnoses will
generally be limited to specialist contexts, and where treatment targeted at the underlying lesion or
disease may be possible [22].
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Diagnosis of neuropathic pain in cancer is no different from other clinical diagnoses, relying
upon comprehensive clinical history, examination and diagnostic tests. The NeuPSIG grading system
and other screening tools can be usefully applied in clinical practice to identify probable cases of
neuropathic pain, with little deviation from normal practice. For example, the NeuPSIG grading
system starts with clinical history. This should include sensory descriptors suggestive of a neuropathic
mechanism (e.g., shooting, pricking, pins and needles, numbness and tingling) with a relevant
neurological lesion, and distribution of these symptoms in the corresponding neuroanatomical
distribution. Clinical examination for sensory changes may be a little more involved than in routine
clinical practice, but is still feasible at the bedside. It involves assessment of touch, vibration, pinprick,
cold and warmth using routinely available tools, such as a cotton bud, tuning fork, toothpick and
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teaspoons in warm and cool water. The grading system indicates that only one sensory abnormality
needs to be present to satisfy this criterion. Lastly, many of the diagnostic tests that would support
a definite diagnosis of neuropathic pain according the NeuPSIG are routinely performed anyway,
such as computed tomography or magnetic resonance imaging. Other more specialist tests may include
neurophysiological tests, such as nerve conduction velocity for example [22].
The NeuPSIG criteria have not yet been universally adopted as the reliability (inter-rater
and test-retest) and applicability in clinical practice and research has not been established [23].
Other screening tools are available for use in clinical and research settings. The most commonly
used neuropathic pain screening tools in research are the Leeds Assessment of Neuropathic
Symptoms and Signs (LANSS) [20], the Douleur Neuropathique en 4 (DN4) [25] and painDETECT
(PDQ) [26]. The LANSS comprises five sensory symptom items and two clinical examination items,
DN4 comprises seven symptom items and three clinical examination items and painDETECT is a
screening questionnaire comprising nine symptom items [27]. These tools were largely developed
in patients without cancer and are biased towards detecting positive sensory abnormalities. NCP
is unique in that pain is often experienced in the presence of sensory loss; therefore, it has been
argued that existing screening tools may not perform adequately in cancer populations. A study in
2017 assessed performance of these screening tools in identifying neuropathic pain in patients with
cancer [23]. They found that LANSS and DN4 screening tools could generally distinguish between
neuropathic and not neuropathic pain in patients with cancer, although not with the same degree of
accuracy as found in non-cancer populations. Nevertheless, these screening tools can be useful in
identifying potential cases of neuropathic pain in cancer until more accurate tools are developed.
Another approach to pain assessment generally reserved for use in research settings is quantitative
sensory testing (QST). QST is a detailed assessment of sensory function and provides information
about the underlying neurobiological mechanisms of pain processing. A standardised QST protocol
published by the German Neuropathic Pain Consortium (DFNS) in 2006 [28] has been widely accepted
in clinical research. However this protocol has had limited impact on clinical practice as QST is labour
intensive and requires highly trained operators with expensive equipment. Nevertheless, QST data
from clinical trials indicate that sensory abnormalities are common in cancer patients with pain [29–32].
These data suggest that integrating simple bedside assessment of sensory function (as described in
the NeuPSIG grading system) may improve the detection and diagnosis of neuropathic cancer pain.
QST data have also demonstrated that the presence of pre-existing sensory deficits (particularly light
touch) prior to chemotherapy are a contributing factor in the onset of painful CIPN [33,34].
4. Management
The evidence base for management of cancer-related neuropathic pain is limited. There is
no clear consensus for first-line or step-wise treatment of cancer-related neuropathic pain [19,35],
which can prove challenging for patients and clinicians alike. Guidelines for pharmacological and
other management of neuropathic cancer pain have recently been published by the European Society
for Medical Oncology (ESMO) [19]. Pharmacological treatment options include opioids, non-opioids
and “adjuvant analgesics”, either alone or in combination. Adjuvant drugs are those traditionally used
for a primary indication other than pain, but with analgesic properties under some circumstances [36].
These agents are often used first-line for neuropathic pain, so the term is something of a misnomer but
is still often used [36,37]. Adjuvant agents used in neuropathic pain include tricyclic antidepressants
(TCAs) and anticonvulsants. Steroids are another adjuvant drug which can be used in cases of
nerve compression causing neuropathic pain. There are strong recommendations against the use of
levetiracetam and mexiletine [19].
Gabapentin, pregabalin, duloxetine and TCAs (doses of ≤75 mg/day) are recommended
in the ESMO guidance as single agents for first-line treatment of neuropathic pain in cancer.
This recommendation has been extrapolated from systematic reviews in non-cancer related neuropathic
pain. For example, a 2015 systematic review and meta-analysis of pharmacotherapy for neuropathic
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pain in adults found that the numbers needed to treat were 3.6 for TCAs, 6.4 for serotonin-noradrenaline
reuptake inhibitors (mainly duloxetine), 7.7 for pregabalin and 7.2 for gabapentin [9]. They also
found that the efficacy of drug treatments was not generally dependent on the underlying cause
of neuropathic pain, which perhaps supports extrapolation of the findings to cancer-related
neuropathic pain.
Some studies have examined the role of adjuvants specifically in neuropathic pain in cancer
but the data are less conclusive. A systematic review in 2017 examined the role of adjuvants in
treating cancer pain, both purely neuropathic and mixed cancer pain [36]. They included gabapentin,
pregabalin, amitriptyline and venlafaxine, and found low quality evidence for these agents in reducing
pain intensity in patients with cancer pain.
Cancer-related neuropathic pain can also be treated using opioids or non-opioids, in combination
with TCAs or anticonvulsants where required. The evidence for this is not conclusive, however.
A systematic review in 2011 examined the effect of adding antidepressant or antiepileptic drugs
to opioids for cancer pain that was largely caused by neuropathic mechanisms. Clinical and
methodological heterogeneity precluded meta-analysis but a narrative analysis found that the addition
of these adjuvants to existing opioid analgesia provided a modest improvement in pain intensity
after 4 to 8 days, but unlikely more than 1 point on a 0–10 numerical rating scale, and with increased
risk of adverse events [38]. The evidence of benefit was strongest for gabapentin. An update to this
review was able to perform meta-analysis of trials that examined the effect of adding antidepressants
or antiepileptics to opioids, comparing cancer pain outcomes between opioid/adjuvant combinations
with opioid monotherapy [39]. This showed no additional improvement in tumour-related pain relief
from adding gabapentinoids to opioids, and an increase in adverse events. However, again the quality
of the evidence was low and benefit for patients with definite neuropathic cancer pain could not
be excluded. The authors concluded that there remains uncertainty regarding the risk-benefit trade
off from combining adjuvants and opioids for treatment of tumour-related cancer pain. The ESMO
guidance advocates careful dosing and monitoring of side effects if using adjuvants in combination
with opioids for neuropathic pain.
Other treatment options discussed in the ESMO guidance include ketamine and interventional
treatments. Ketamine is an N-methyl-D-aspartate (NMDA) antagonist which has been used to treat
refractory cancer pain, including neuropathic pain, but current evidence is insufficient to determine
the benefits and harms associated with this treatment [40]. Interventional treatments of neuropathic
pain in cancer are not recommended in the ESMO guidelines as the evidence is weak or inconclusive,
unless used for neuropathic pain syndromes unrelated to cancer [19].
Another evolving approach to analgesia, including in cancer-related neuropathic pain, is the
concept of mechanism-based pain management [41,42]. This involves assessment of pain aetiology
(e.g., inflammatory or neuropathic), location of pain-generating mechanism (e.g., peripheral or central
sensitisation) and corresponding molecular targets (e.g., nerve growth factors) [42]. This is an exciting
area of research with myriad potential new analgesic targets, but at present there are no licensed
targeted treatments and no clinical studies demonstrating efficacy in cancer patients.
Non-pharmacological interventions are also important in multimodal management of neuropathic
cancer pain, as in all forms of cancer pain. It is well-recognised that inadequate patient education can
provide a barrier to effective pain management in cancer [43,44]. There is also increasing evidence of
the importance and effectiveness of patient education in reducing pain intensity and pain interference
in cancer patients [45,46]. Self-management interventions for people with cancer pain are one
such example. These aim to increase patients’ knowledge, skills and confidence to manage their
condition [47], and importantly, to become active in their own management [48].
5. Future Research
Considerable future research challenges for neuropathic pain in cancer lie ahead. Priority areas for
research include cancer pain assessment, pain neurobiology and targeted therapies. Comprehensive
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and accurate cancer pain assessment is essential, not only to differentiate neuropathic from nociceptive
pain, but also in more precisely profiling the characteristics of neuropathic pain. It is increasingly
recognised that neuropathic pain actually comprises a range of different subgroups or so-called
sensory profiles [49,50]. These may result from different neurobiological mechanisms, and so may
respond differently to treatments tailored to these. Therefore, careful pain assessment can indicate pain
mechanisms and guide targeted therapy, improving pain outcomes but also improving the evidence
base for treatment of this particularly challenging symptom.
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